PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'New York University Langone Vaccine Center, New York, NY, USA.\', \'New York University Grossman School of Medicine, New York, NY, USA.\', \'University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD, USA.\', \'Vaccine Research and Development, Pfizer Inc, Hurley, UK.\', \'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA. judith.absalon@pfizer.com.\', \'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.\', \'Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.\', \'University of Texas Medical Branch, Galveston, TX, USA.\', \'BioNTech, Mainz, Germany.\', \'University of Rochester, Rochester, NY, USA.\', \'Rochester General Hospital, Rochester, NY, USA.\', \'Cincinnati Children\'s Hospital, Cincinnati, OH, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41586-020-2639-4
?:doi
?:hasPublicationType
?:journal
  • Nature
is ?:pmid of
?:pmid
?:pmid
  • 32785213
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.875
?:rankingScore_hIndex
  • 1052
?:title
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32785213>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32785213>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all